[go: up one dir, main page]

AR057467A1 - Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas - Google Patents

Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas

Info

Publication number
AR057467A1
AR057467A1 ARP060103071A ARP060103071A AR057467A1 AR 057467 A1 AR057467 A1 AR 057467A1 AR P060103071 A ARP060103071 A AR P060103071A AR P060103071 A ARP060103071 A AR P060103071A AR 057467 A1 AR057467 A1 AR 057467A1
Authority
AR
Argentina
Prior art keywords
methyl
phenyl
trifluorometil
imidazol
preparation
Prior art date
Application number
ARP060103071A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37398525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057467(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR057467A1 publication Critical patent/AR057467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Método de preparacion de dichos compuestos, composiciones farmacéuticas que los componen y usos. Reivindicacion 1: Una sal de 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida.
ARP060103071A 2005-07-20 2006-07-18 Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas AR057467A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70140605P 2005-07-20 2005-07-20
US71621305P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
AR057467A1 true AR057467A1 (es) 2007-12-05

Family

ID=37398525

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103071A AR057467A1 (es) 2005-07-20 2006-07-18 Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas

Country Status (33)

Country Link
US (4) US8163904B2 (es)
EP (2) EP2186808B1 (es)
JP (1) JP5129132B2 (es)
KR (3) KR20140047737A (es)
CN (1) CN102267981A (es)
AR (1) AR057467A1 (es)
AT (1) ATE514689T1 (es)
AU (2) AU2006276205C1 (es)
BR (1) BRPI0613605A2 (es)
CA (2) CA2615669C (es)
CY (1) CY1111772T1 (es)
DK (1) DK1910336T3 (es)
EC (1) ECSP088118A (es)
ES (1) ES2634291T3 (es)
GT (1) GT200600316A (es)
HR (1) HRP20110639T1 (es)
IL (1) IL187787A (es)
JO (1) JO2757B1 (es)
MA (1) MA29686B1 (es)
MX (1) MX2008000892A (es)
MY (1) MY149889A (es)
NO (1) NO341313B1 (es)
NZ (2) NZ591142A (es)
PE (1) PE20070241A1 (es)
PL (1) PL1910336T3 (es)
PT (1) PT1910336E (es)
RU (4) RU2483065C2 (es)
SG (1) SG170772A1 (es)
SI (1) SI1910336T1 (es)
TN (1) TNSN08028A1 (es)
TW (1) TWI455934B (es)
UY (1) UY29683A1 (es)
WO (1) WO2007015871A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
CA2644841C (en) * 2006-04-07 2013-07-16 Novartis Ag Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2010009402A2 (en) 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
ES2394258T3 (es) 2008-11-05 2013-01-30 Teva Pharmaceutical Industries Ltd. Formas cristalinas de Nilotinib HCL
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
RU2011140404A (ru) 2009-03-06 2013-04-20 Новартис Аг Применение производных пиримидиламинобензамида для лечения нарушений, опосредованных киназой, содержащей мотив лейциновой "молнии" и стерильный альфа мотив (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
WO2011033307A1 (en) 2009-09-17 2011-03-24 Generics [Uk] Limited Nilotinib dihydrochloride salt
MX2012004709A (es) 2009-10-23 2012-05-23 Novartis Ag Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (es) 2010-01-15 2016-09-02
JP2013525296A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 内分泌療法抵抗性乳癌の処置
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
US8937082B2 (en) 2010-06-21 2015-01-20 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
WO2012014127A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
US8703788B2 (en) * 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
PH12014500897A1 (en) 2011-10-28 2019-10-07 Novartis Ag Method of treating gastrointestinal stromal tumors
AR088844A1 (es) 2011-11-14 2014-07-10 Novartis Ag Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
BR112015000349A2 (pt) 2012-07-11 2017-06-27 Novartis Ag método de tratamento de tumores estromais gastrointestinais
EP2906554A4 (en) * 2012-10-15 2016-06-29 Apotex Inc SOLID FORMS OF NILOTINIB HYDROCHLORIDE
US9567317B2 (en) 2012-10-19 2017-02-14 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CA2912902A1 (en) 2013-04-24 2014-10-30 Dr. Reddy's Laboratories Limited Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
EP3177610A4 (en) 2014-08-08 2018-01-10 Dr. Reddy's Laboratories Ltd. Process for the preparation of polymorphic forms of nilotinib
HRP20220358T1 (hr) 2014-08-11 2022-05-13 Sun Pharmaceutical Industries Limited Nove soli nilotiniba i njihovi polimorfi
US10301282B2 (en) 2015-03-20 2019-05-28 Cipla Limited Polymorphic form X of nilotinib dihydrochloride hydrate
EP3408264B1 (en) 2016-01-26 2020-03-11 Farma GRS, d.o.o. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
RS60939B1 (sr) 2016-03-14 2020-11-30 Pliva Hrvatska D O O Čvrsti oblici soli nilotiniba
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN112423757A (zh) * 2018-06-15 2021-02-26 汉达生技医药责任有限公司 激酶抑制剂的盐类及其组合物
WO2020095187A1 (en) * 2018-11-05 2020-05-14 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
ES2993251T3 (en) 2019-02-18 2024-12-26 Slayback Pharma Llc Pharmaceutical compositions of nilotinib
CA3168680A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP4103560A1 (en) * 2020-02-15 2022-12-21 Cipla Limited Novel salts of nilotinib and polymorphic forms thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
JP2023543815A (ja) 2020-09-29 2023-10-18 シェンチェン ファーマシン シーオー．，エルティーディー． 医薬組成物
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
EP4642435A1 (en) 2022-12-29 2025-11-05 Renata Pharmaceuticals (Ireland) Limited Pharmaceutical suspension of nilotinib
US12419892B2 (en) 2023-11-08 2025-09-23 Xspray Pharma Ab Pharmaceutical compositions comprising nilotinib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2081108C1 (ru) * 1991-10-16 1997-06-10 Циба-Гейги АГ Аддитивные соли кислот с основанием и фармацевтическая композиция, обладающая противоопухолевой активностью
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
CA2148928C (en) 1993-10-01 2005-10-18 Jurg Zimmermann Pharmacologically active pyridine derivatives and processes for the preparation thereof
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
WO2001044195A1 (en) * 1999-12-14 2001-06-21 Nippon Shinyaku Co., Ltd. Heterocycle derivatives and drugs
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
PE20051096A1 (es) * 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
SA06270147B1 (ar) * 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Also Published As

Publication number Publication date
CN102267981A (zh) 2011-12-07
RU2011120363A (ru) 2012-11-27
CA2615669C (en) 2013-11-12
AU2010241419B2 (en) 2012-03-29
KR101755137B1 (ko) 2017-07-06
GT200600316A (es) 2007-04-02
SG170772A1 (en) 2011-05-30
US20120270891A1 (en) 2012-10-25
PL1910336T3 (pl) 2011-11-30
CA2823946C (en) 2015-12-29
IL187787A (en) 2012-07-31
US8580806B2 (en) 2013-11-12
CA2615669A1 (en) 2007-02-08
US8163904B2 (en) 2012-04-24
MX2008000892A (es) 2008-03-18
RU2483065C2 (ru) 2013-05-27
MY149889A (en) 2013-10-31
CY1111772T1 (el) 2015-10-07
KR20140047737A (ko) 2014-04-22
RU2434864C2 (ru) 2011-11-27
RU2605551C2 (ru) 2016-12-20
PE20070241A1 (es) 2007-03-22
RU2013101749A (ru) 2014-07-27
JO2757B1 (en) 2014-03-15
MA29686B1 (fr) 2008-08-01
EP2186808B1 (en) 2017-04-19
US9163005B2 (en) 2015-10-20
TNSN08028A1 (en) 2009-07-14
AU2010241419C1 (en) 2024-05-23
TW200800950A (en) 2008-01-01
EP1910336A1 (en) 2008-04-16
WO2007015871A1 (en) 2007-02-08
NZ564182A (en) 2011-03-31
US20080200487A1 (en) 2008-08-21
NZ591142A (en) 2012-09-28
AU2010241419A1 (en) 2010-12-02
RU2008105827A (ru) 2009-08-27
CA2823946A1 (en) 2007-02-08
ECSP088118A (es) 2008-02-20
TWI455934B (zh) 2014-10-11
RU2509767C1 (ru) 2014-03-20
NO341313B1 (no) 2017-10-09
PT1910336E (pt) 2011-09-05
EP2186808A1 (en) 2010-05-19
HK1116778A1 (en) 2009-01-02
ATE514689T1 (de) 2011-07-15
NO20080897L (no) 2008-02-20
KR20080027855A (ko) 2008-03-28
BRPI0613605A2 (pt) 2011-01-18
US8389537B2 (en) 2013-03-05
HRP20110639T1 (hr) 2011-10-31
US20140038994A1 (en) 2014-02-06
JP2009502796A (ja) 2009-01-29
AU2006276205A1 (en) 2007-02-08
SI1910336T1 (sl) 2011-10-28
DK1910336T3 (da) 2011-10-03
US20130137712A1 (en) 2013-05-30
JP5129132B2 (ja) 2013-01-23
IL187787A0 (en) 2008-08-07
AU2006276205B2 (en) 2010-08-19
KR20150100946A (ko) 2015-09-02
EP1910336B1 (en) 2011-06-29
UY29683A1 (es) 2007-02-28
AU2006276205C1 (en) 2024-08-01
ES2634291T3 (es) 2017-09-27

Similar Documents

Publication Publication Date Title
AR057467A1 (es) Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas
CY1119624T1 (el) Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
CR11333A (es) cis-IMIDAZOLINAS QUIRALES
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
NO20071880L (no) Diagnostic Compounds
DE602005014382D1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
SE0301653D0 (sv) Novel compounds
EA201070689A1 (ru) Композиция для личного ухода
SE0302546D0 (sv) New compounds
NO20060021L (no) Trelim
NO20082989L (no) Fremstiling av gamma-aminosyrer som har affinitet for alfa-2-deltaproteinet
CL2011003138A1 (es) N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion.
NO20062705L (no) Antimikrobiell sammensetning anvendbar for impregnering av treverk
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
EA200801414A1 (ru) Кальцилитические соединения
AR051796A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas
CY1110942T1 (el) Αλας αιθανολαμινης n-(3-μεθοξυ-αιθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολο -2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδιου
EA200901551A1 (ru) Бензамиды, применимые в качестве модуляторов рецептора s1p
EA201000611A1 (ru) 4,4-дизамещенные пиперидины
UY29712A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure